Entaliv 0.5mg Tablet

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Entaliv 0.5mg Tablet also causes some adverse impact on the body, most of which resolve without any medical attention.
Some common side effects include:
Fever
Nausea
Joint pain
Vomiting
Fatigue
Abdominal pain
Poor appetite
Itching
Dark yellow urine & stools
Jaundice
Pale skin
Unusual tiredness
Contact your doctor immediately if you experience any severe or unusual side effects.

The dosage of Entaliv 0.5mg Tablet is determined by the doctor based on your health condition. This medication should be taken orally on an empty stomach, or it can be consumed one hour before a meal or two hours after a meal. In the event of an overdose, contact your doctor immediately.

Entaliv 0.5mg Tablet is a prescription-based antiviral medicine. It works by inhibiting the synthesis of DNA, which reduces the viral load in the body. It also suppresses the replication/ multiplication of HBV. Taking this medicine results in improved liver conditions as the inflammation reduces over time, and it further prevents liver damage.

It is advised not to miss any scheduled dosage of Entaliv 0.5mg Tablet. In case you miss a dose, consult your doctor immediately.

Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

• Go for a liver function test once you start the treatment to ensure normal functioning of the organ.

• Do not share your medicine with other people, as some medicines treat specific genotypes of Hepatitis.

• Some Hepatitis medicines are given in combination with other antiviral drugs. So, it is advised not to use them alone.

• Hepatitis medicines are also given to treat HIV/ AIDS patients in some cases. But these medicines are not the proper treatment for this disease.

• It is advised to use effective birth control methods to avoid pregnancy. Some hepatitis drugs can cause birth defects, miscarriage, or death to an unborn baby if the mother or father is using this medicine.

• It is advised to tell your doctor about all medicines (multivitamins, herbal supplements) you're taking currently before starting your course with hepatitis medicines. There are chances that many drugs can interact, and some drugs should not be used together.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. Matthews, S. J. (2006). Entecavir for the treatment of chronic hepatitis B virus infection. Clinical therapeutics, 28(2), 184-203.
2. Wong, V. W. S., Wong, G. L. H., Yiu, K. K. L., Chim, A. M. L., Chu, S. H. T., Chan, H. Y., ... & Chan, H. L. Y. (2011). Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of hepatology, 54(2), 236-242.
3. Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., ... & Kumada, H. (2013). Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology, 58(1), 98-107.
4. Rivkin, A. (2005). A review of entecavir in the treatment of chronic hepatitis B infection. Current medical research and opinion, 21(11), 1845-1856.
5. Jin, X., Chen, Y. P., Yang, Y. D., Li, Y. M., Zheng, L., & Xu, C. Q. (2012). Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. PLoS one, 7(3), e34198.